Gadopentetic acid Inhibitor

The initial concentration of Gadopentetic acid (Gd-DTPA) in the plasma ([Gd-DTPA0]) is an important parameter for DCE-MRI. [Gd-DTPA0] is related to the administered bolus dose and varies with subjects. A bolus of 0.025 mmol/kg Gd-DTPA offers shorter acquisition time and less exposure of subjects, with a half-life of 37.3 mins, a mean residence time of 53.8 mins, and an AUC of 3.37 +/- 0.47 mmol/min/L.Gadopentetic acid (Gd-DTPA) is an paramagnetic contrast agent commonly implemented by a bolus intravenous injection (i.v.) in Dynamic contrast-enhanced MRI (DCE-MRI) studies.

Wan C, et al. Gd-DTPA-induced dynamic metabonomic changes in rat biofluids. Magn Reson Imaging. 2017 Dec;44:15-25.
Wan C, et al. Gd-DTPA-induced dynamic metabonomic changes in rat biofluids. Magn Reson Imaging. 2017 Dec;44:15-25.
Taheri S, et al. Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2016 Sep;34(7):1034-40.
Taheri S, et al. Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2016 Sep;34(7):1034-40.

Small volumes of Gadopentetic acid, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756010 is an inhibitor targeting Gadopentetic acid.